Narcolepsy is a chronic sleep disorder that carries a high degree of disability and comorbidity. Patients often wait years for a proper diagnosis and treatment initiation, resulting in a tremendous negative impact to their quality of life. Pharmacotherapy for narcolepsy has historically been limited to traditional stimulants and twice-nightly GABA-B receptor agonist sodium oxybate. But recently, novel agents have been FDA approved, including solriamfetol, pitolisant, and once-nightly extended-release sodium oxybate, offering additional mechanisms and dosing regimens to positively impact patient care.
During this podcast, sleep experts will discuss the latest clinical trials on the safety and efficacy of currently available novel therapies for EDS and cataplexy in patients with narcolepsy as well as strategies to improve treatment adherence.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant from Avadel CNS Pharmaceuticals, LLC.
Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care practitioners (PCPs), physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 0.75 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.
Note to Nurse Practitioners: the content of this CNE activity pertains to Pharmacology.
This application-based activity is approved for 0.75 contact hours ( 0.075 CEUs) of continuing pharmacy credit ( JA0007185-0000-24-016-H01-P ).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 02/26/25. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Morse reports the following financial relationships:
Advisory Board: Alkermes; Avadel Pharmaceuticals; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation
Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.
Speakers Bureau: Jazz Pharmaceuticals, Inc.
Employment: DAMM Good Sleep, LLC (CEO)
Dr. Kushida reports the following financial relationships:
Advisory Board: Avadel Pharmaceuticals; Cerebra Heath Inc.; and Samsung
Consultant: Asleep Inc.; Eisai Inc.; Genentech, Inc.; Koko Home, Inc.; Morgan Stanley; Oxama Medical; Restful Robotics Inc.; Sound Health Inc.; and Vivos Therapeutics, Inc.
Research Support: Avadel Pharmaceuticals; and Eisai Inc.
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell (Planning Committee)
Erin Spencer, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
PD-105-022624-76